ZALTRAP
Zaltrap (ziv-aflibercept) is a vascular endothelial growth factor inhibitor indicated for the treatment of patients with metastatic colorectal cancer. It is used in combination with the FOLFIRI chemotherapy regimen, which includes fluorouracil, leucovorin, and irinotecan. This treatment is specifically for patients whose disease has progressed on or is resistant to a prior chemotherapy regimen containing oxaliplatin.
How ZALTRAP Works
Ziv-aflibercept functions as a soluble receptor that binds to human VEGF-A, VEGF-B, and placental growth factor (PlGF). By binding to these endogenous ligands, the drug prevents them from interacting with and activating their cognate receptors. This inhibition results in decreased neovascularization and vascular permeability, which hinders the proliferation of endothelial cells and the growth of new blood vessels.
Details
- Status
- Prescription
- First Approved
- 2012-08-03
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
ZALTRAP Approval History
What ZALTRAP Treats
1 indicationsZALTRAP is approved for 1 conditions since its original approval in 2012. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Colorectal Cancer
ZALTRAP Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
ZALTRAP Competitors
Pro6 other drugs also target VEGF. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGF). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to ZALTRAP
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ZALTRAP FDA Label Details
ProIndications & Usage
FDA Label (PDF)ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. ZALTRAP, a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.